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Summary
With the technical developments in neurosurgery, increas-
ing numbers of neurosurgical implants are used in an in-
creasingly aged population of patients with several co-
morbidities. Consequently, the number of neurosurgical
implant-associated infections is continuously raising, re-
sulting in significant morbidity and mortality, including dis-
figuring skull deformities and lack of brain protection. In
this article we review infections associated with cranioto-
my, cranioplasty, neurostimulators, internal cerebrospinal
fluid shunts, and external ventricular and lumbar cere-
brospinal fluid drainages.
In all implant-associated infections biofilms are involved,
which are difficult to eradicate. A low number of microor-
ganisms is sufficient to form a biofilm on the implant sur-
face. In most infections, microorganisms of the skin flora
are involved. Microorganisms reach the implant during
surgery or immediately thereafter as a result of wound
healing disturbances. In about two thirds of patients, im-
plant-associated infections manifest early (within the first
month after surgery), whereas the remaining infections
present later as a result of low-grade infections or by direct
extension from adjacent infections (per continuitatem) to
the implants due to soft tissue damage. Except for ven-
triculo-atrial cerebrospinal fluid shunts, neurosurgical im-
plants are rarely infected by the haematogenous route.
In this article we review established and clinically validated
concepts for the management of biofilm-associated infec-
tions in orthopaedic and trauma surgery, which can be ex-
trapolated to other surgical disciplines that use implants.
However, the evidence for the success of this extrapola-
tion to neurosurgical patients is sparse and has not been
evaluated in large patient populations. For favourable out-
come, an optimised microbiological diagnosis including
sonication of removed implants and prolonged incubation
of cultures is required. Furthermore, a combined surgical
and antimicrobial management strategy is needed.
Surgery includes an appropriate debridement with or with-
out implant exchange or removal, depending on the age
of the biofilm and the soft tissue condition. Antimicrobial
treatment includes a prolonged biofilm-active therapy, typi-
cally for 4–12 weeks. This concept is attractive, because in
selected patients, implants can be retained or exchanged
in a one-stage surgical procedure, which improves not on-
ly quality of life, but also decreases morbidity because
every additional neurosurgical intervention can lead to
secondary complications, including intracerebral bleeding
or ischemia.
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Introduction
An increasing number of implant insertions are observed
in all surgical disciplines, including neurosurgery. Indica-
tions are degenerative and age-related, but also ischaemic,
neoplastic and trauma-related health problems. In 2004,
an estimated 450,000 neurosurgical implants were inserted
in the United States [1]. Implant-associated infections oc-
cur in about 3–15%, which is 0.3–12% for craniotomies,
1–24.4% for craniectomies, 1–6% for neurostimulators,
4–17% for cerebrospinal fluid (CSF) shunts, 2–22% for
external ventricular CSF drainages (EVD) and 5% for ex-
ternal lumbar CSF drainages (ELD) [1, 2]. These infec-
tions can be devastating for the patient and are associated
with increased morbidity and mortality, as usually more
than one revision operation is needed and the patient is
left with unaesthetic skull deformities without brain pro-
tection in between; in addition pain, movement disorders
and depressive symptoms can deteriorate [3, 4]. Therefore,
the management of neurosurgical implant-associated infec-
tions is of high importance.
Diagnosis of neurosurgical implant-associated infections
is challenging [5]. Clinical signs and symptoms are often
nonspecific, insensitive and difficult to interpret in the con-
text of neurologically disabled patients after intracerebral
bleeding or trauma and in patients with impaired con-
sciousness due to the treatment with sedative drugs. The
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same is true for laboratory tests including CSF parameters.
A thoughtful approach to the patient is necessary, which in-
cludes observation of the dynamic of the clinical evolution
and laboratory tests, and considers as well the time interval
from surgery and the presence of other nosocomial infec-
tious foci [2].
Implant surfaces are highly susceptible to bacterial coloni-
sation and within a few minutes a biofilm is formed [6, 7].
Biofilms complicate microbiological diagnosis and treat-
ment of implant-associated infections, because bacteria in
biofilms live in a dormant state and are not planktonic in
tissue or CSF [8, 9]. Most neurosurgical implants are in-
fected exogenously by contamination with microorganisms
of the skin or mucosal flora during surgery or in the first
days postoperatively during wound healing disturbance.
Therefore, more than two thirds of patients present within
the first month of surgery [6, 7, 10, 11]. Haematogenous
seeding from a distant infectious focus is rare, and almost
exclusively found in ventriculo-atrial (VA) shunts owing to
their intravascular position.
Standardised approaches to the management of neurosur-
gical implant-associated infections are lacking. The extrap-
olation of well-established concepts from orthopaedic and
trauma surgery dealing with implant-associated infections
seems attractive and logical, as these have been clinical-
ly validated and proven successful [12–14]. Microbiolog-
ical diagnosis can be optimised by sonication of removed
implants and prolonged incubation of cultures for up to
14 days [15, 16]. Interdisciplinary treatment consists of a
combined surgical and antimicrobial approach. Surgery al-
ways includes debridement and either implant retention,
exchange or removal. In addition, a prolonged antimicro-
bial biofilm-active treatment is needed [17]. It is important
to note that in neurosurgery removal or exchange of im-
plants and extensive debridement are not always feasible
because of secondary damage to the central nervous sys-
tem (CNS), and that antimicrobial penetration across the
blood-brain barrier is critical.
This review aims to discuss diagnostic and treatment chal-
lenges in neurosurgical implant-associated infections and
to extrapolate interdisciplinary management concepts from
implant-associated infections in orthopaedic and trauma
surgery, where the concept is established and clinically val-
idated. However, the evidence for the success of this ex-
trapolation to neurosurgical patients is sparse and has not
been evaluated in large patient populations. Infections as-
sociated with craniotomy, cranioplasty, neurostimulators,
internal CSF shunts (ventriculo-peritoneal [VP] and VA
shunts), as well as EVD and ELD will be covered.
Classification of neurosurgical implant-associ-
ated infections
Implant-associated infections are classified according to
the time-point of manifestation after implantation and ac-
cording to the acuity of infection, because the two para-
meters (together with the detected microorganism) define
infection management [10, 17, 18]. The classification in-
cludes acute and chronic infections (table 1). Acute in-
fections present early, typically within 6 weeks of im-
plantation. Patients usually have fever and signs of local
inflammation with pain, heat, swelling, redness and a pu-
trid wound discharge. Chronic infections, on the other
hand, present later, often months after implantation. Pa-
tients usually have discrete signs of local inflammation,
but may present with persisting wound discharge, fistula or
implant on view. In acute infections an immature biofilm is
present, therefore eradication of infection can be achieved
by implant debridement and retention, and a 12-week
biofilm-active treatment, whereas in chronic infections a
mature biofilm is present, which cannot be eradicated with-
out implant removal or exchange [9, 14, 19–22]. EVD and
ELD are non-permanent implants, therefore this classifica-
tion does not apply to them. They usually can be removed
if an infection occurs and therefore no biofilm-active ther-
apy is needed.
Diagnostic concepts for neurosurgical implant-
associated infections
Sonication of the removed implants and prolonged incuba-
tion of cultures for up to 14 days became the standard of
care, as most low-virulent pathogens require 7–14 days of
cultivation [15, 16]. However, with longer sample cultiva-
tion the risk of contamination increases, and the microbi-
ological results need to be interpreted accordingly. Speci-
ficity of sonication in orthopaedic surgery is high (up to
99%) and sensitivity is significantly higher than for tissue
cultures, because biofilms are detached from the implant
surface and cultured (sensitivity 80–90% vs 60% in tis-
sue cultures). This is especially true for patients with an-
timicrobial pretreatment (sensitivity 75 vs 45%) [15]. As
biofilms are patchily distributed in the periimplant tissue,
several (ideally three to five) independent tissue samples
are recommended. In culture-negative infections, mole-
cular diagnostic testing such as polymerase chain reac-
tion tests or next-generation sequencing may identify the
pathogen.
In neurosurgery, sonication has been proven useful for os-
teosynthesis (as used for craniotomy fixation), cranioplas-
ties, CSF shunts and EVD tips [23–26]. Prinz et al. son-
icated VP shunts in 22 patients and compared them with
13 patients with conventional culture only [26]. Sonication
detected the pathogen in all cases, whereas conventional
culture in only 61% (p = 0.018). When pathogen detection
was analysed by method, sonication was positive in all in
whom it was performed, and culture in only 22 of 35 pa-
tients (60%, p <0.001). For patients with antimicrobial pre-
treatment (n = 18), sonication again was positive in all 12
patients, but conventional culture only in 3 of 6 patients
(50%, p = 0.005), underlining the high diagnostic impact
Table 1: Classification of implant-associated infections according to the time of occurrence.
Acute infection* Chronic infection
Time-point ≤6 weeks after implantation >6 weeks after implantation
Biofilm Immature Mature
Treatment concept Debridement and implant retention Removal or exchange of implant in a one- or two-stage procedure
* Late haematogenous infections in neurosurgical implants are very rare and apply mainly to ventriculo-atrial shunt-associated infections
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of sonication. The same was true for EVD-associated in-
fections in a smaller study by Jost et al. [25]. In 14 patients
sonication of the EVD tip was performed and had a high-
er detection rate than conventional culture of ventricular
CSF (64 vs 14%; p <0.05), which can be explained by the
biofilm concept, where microorganisms attach to the im-
plant surface and are not planktonic in the CSF. Neverthe-
less, contamination is still possible if the EVD tip is not
properly collected (need for disinfection of cutaneous exit
site before pulling out the catheter, collection of the distal
2–3 cm of the drainage). Five patients had a positive soni-
cation culture, but a negative CSF culture and the findings
were initially rated as contamination, but two of them suf-
fered a meningitis episode a few days after EVD removal.
Treatment concepts for neurosurgical implant-
associated infections
In permanent neurosurgical implants (i.e., except EVD and
ELD), the treatment concepts as described in orthopaedic
and trauma surgery can be extrapolated, although the ev-
idence for this extrapolation is sparse and not validated
in large neurosurgical patient populations [17, 18]. To
achieve high treatment success, an interdisciplinary man-
agement is needed including surgery and biofilm-active
therapy. Surgical debridement is always necessary to re-
move the necrotic tissue and to mechanically reduce the
pathogen load in established biofilms. The implant man-
agement depends on the acuity and time of infection after
device implantation, and includes debridement and reten-
tion in acute infections and one- or two-stage exchange
or implant removal in chronic infections (fig. 1). In addi-
tion, it is of utmost importance to have adequate postoper-
ative soft tissue coverage of the implant to avoid secondary
implant colonisation with skin pathogens. Thereafter, a
biofilm-active therapy is given for usually 4–12 weeks
(1–2 weeks intravenous and 3–10 weeks oral treatment),
depending on the duration of the implant-free interval and
the intraoperative culture results. A drug holiday (antibi-
otic-free period before reimplantation) is not recommend-
ed since neurosurgical patients are often in urgent need of
the implant not only to avoid disfiguring skull deformi-
ties and lack of brain protection, but also to decrease the
risk of the development of a sinking flap syndrome with
progressive neurological deterioration. In addition, in ex-
trapolation from the orthopaedic literature, in periprosthet-
ic joint infections it was demonstrated that the outcome
was better with continuous antibiotic therapy than with an
antibiotic-free interval before reimplantation [27]. The ra-
tionale for continuous antibiotic therapy is that there is no
diagnostic test that can accurately exclude persistent infec-
tion at the time of reimplantation and any viable organism
can cause a relapse of infection. Therefore, treatment af-
ter reimplantation should be continued to complete a full
treatment course for implant-associated infections. Treat-
ment failure in neurosurgical implant-associated infections
is a devastating situation and must be absolutely avoided.
Bactericidal antimicrobial drugs with penetration into the
CSF should be used if needed (tables 2, 3 and 4) [17, 18,
28].
Biofilm-active treatment against gram-positive pathogens
(staphylococci and Cutibacterium spp.) relies on bacteri-
cidal rifampin combinations; against gram-negative bacilli
it relies on fluoroquinolones. Rifampin (reaching 56% of
plasma levels in CSF) should not be administered as a sin-
gle antibiotic since resistance rapidly emerges; therefore it
has to be combined with an antibiotic with similarly good
Figure 1: Treatment algorithm for implant-associated infections. Criteria for implant debridement and retention: acute infection (≤6 weeks
postoperative), adequate soft tissue coverage, no implant dysfunction, availability of biofilm-active treatment, absence of life-threatening infec-
tion (e.g., brain abscess or meningitis). Antibiotics with biofilm activity: rifampin for staphylococci and Cutibacterium spp.; fluoroquinolones for
gram-negative bacilli.IV = intravenous; w = week(s)
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CSF penetration, such as cotrimoxazole (40–50% of plas-
ma levels in CSF), levofloxacin (30–50% of plasma levels
in CSF), moxifloxacin (>50% of plasma levels in CSF) and
doxycycline (26% of plasma levels in CSF) [29]. In CSF
shunt-associated infections, emergence of rifampin resis-
tance has been observed when coagulase-negative staphy-
lococci were treated with intravenous vancomycin, which
has insufficient CSF penetration and therefore results in a
Table 2: Empirical intravenous treatment for intra- and extradural infections (local susceptibility data and patient’s renal function and body weight must be taken into account).
Localisation First choice Alternative
Extradural infection
(craniotomy- or cranioplasty-associated infections, epidural
empyema)
Amoxicillin/clavulanic acid 3 × 2.2 g* OR
Ampicillin/sulbactam 3 × 3 g
Cefuroxime 3 × 1.5 g
– With implants in place PLUS vancomycin†‡ 2 × 15 mg/kg PLUS daptomycin‡ 1 × 8 mg/kg
Intradural infection
(subdural empyema, meningitis, brain abscess)
Cefepime 3 × 2 g Meropenem 3 × 2 g
– With implants in place PLUS vancomycin†‡ 2 × 15 mg/kg PLUS vancomycin†‡ 2 × 15 mg/kg
* If the higher dosage form of 2.2 g is not available, 3 × 1.2 g can be used instead. † A single loading dose can be used in critically ill patients (1 × 25–30 mg/kg). Vancomycin
trough serum concentration: 15–20 mg/l, measure after any dosage change before the fourth dose and at any relevant change of serum creatinine. ‡ Intravenous fosfomycin (for
extradural infections 3 × 5 g and for intradural infections 3 × 8 g) is an alternative to vancomycin or daptomycin, but is not available in all countries for this indication. In Germany,
a 5-g fosfomycin dosage form for intravenous use is available; in most other countries, 2-, 4- and 8-g dosage forms of intravenous fosfomycin are available. A daily dosage of
12–24 g of intravenous fosfomycin is licensed, which can be administered as 3–4 × 5 g, 2–3 × 8 g or 3–6 × 4 g.
Table 3: Targeted intravenous treatment for intra- and extradural infections (patient’s renal function and body weight must be taken into account). Rifampin treatment is indicated
only if an implant is involved.
Pathogen Extradural infection Intradural infection
Staphylococcus spp. Methicillin-susceptible Flucloxacillin 4 × 2 g
PLUS consider
fosfomycin* 3 × 5 g
Flucloxacillin 6 × 2 g
PLUS consider
fosfomycin* 3 × 8 g
Allergy to penicillin (none type 1) Cefazolin 3 × 2g
PLUS consider
fosfomycin* 3 × 5 g
Cefepime 3 × 2 g OR
meropenem 3 × 2 g
for both PLUS consider
fosfomycin* 3 × 8 g
Methicillin-resistant or allergy to penicillin
(type 1)
Vancomycin† 2 × 15 mg/kg OR
daptomycin 1 × 8 mg/kg
for both PLUS consider
fosfomycin* 3 × 5 g
Cotrimoxazole 3 × 1920 mg p.o. OR
vancomycin† 2 × 15 mg/kg
for both PLUS consider
fosfomycin* 3 × 8 g
For all staphylococcal infections with im-
plants in place
PLUS rifampin‡ 2 × 450 mg p.o. PLUS rifampin‡ 2 × 600 mg p.o.
Streptococcus spp. Penicillin G 4 × 5 mio. IU OR
ceftriaxone 1 × 2 g
Penicillin G 4 × 5 mio. IU OR
ceftriaxone 2 × 2 g
Enterococcus faecalis Penicillin-susceptible Ampicillin 4 × 2 g
PLUS
gentamicin§ 1 × 3 mg/kg OR
ceftriaxone 2 × 2 g
Ampicillin 6 × 2 g
PLUS
gentamicin§ 1 × 3 mg/kg OR
ceftriaxone 2 × 2 g
Penicillin-resistant Vancomycin† 2 × 15 mg/kg
PLUS
gentamicin§ 1 × 3 mg/kg
Vancomycin† 2 × 15 mg/kg
PLUS
gentamicin§ 1 × 3 mg/kg
Enterococcus faecium Penicillin-susceptible Ampicillin 4 × 2g
PLUS
gentamicin§ 1 × 3 mg/kg
Ampicillin 6 × 2 g
PLUS
gentamicin§ 1 × 3 mg/kg
Penicillin-resistant Vancomycin† 2 × 15 mg/kg
PLUS
gentamicin§ 1 × 3 mg/kg
Vancomycin† 2 × 15 mg/kg
PLUS
gentamicin§ 1 × 3 mg/kg
Cutibacterium spp. Penicillin G 4 × 5 mio. IU OR
ceftriaxone 1 × 2 g
Penicillin G 4 x 5 mio. IU OR
Ceftriaxone 2 × 2g
– With implants in place PLUS rifampin‡ 2 × 450 mg p.o. PLUS rifampin‡ 2 × 600 mg p.o.
Enterobacteriaceae Ceftriaxone 1 × 2 g OR
amoxicillin/clavulanic acid 3 × 2.2 g¶ OR
ampicillin/sulbactam 3 × 3 g
Ceftriaxone 2 × 2 g
Non-fermenters
(e.g., Pseudomonas aeruginosa, Acinetobacter spp.)
Ceftazidime 3 × 2 g OR
cefepime 3 × 2 g OR
piperacillin/tazobactam 3–4 × 4.5 g OR
meropenem 3 × 2 g
Ceftazidime 3 × 2 g OR
cefepime 3 × 2 g OR
meropenem 3 × 2 g
Culture-negative infections Amoxicillin/clavulanic acid 3 × 2.2 g¶
OR
ampicillin/sulbactam 3 × 3 g
both PLUS
vancomycin† 2 × 15 mg/kg
Ceftriaxone 2 × 2 g
PLUS
vancomycin† 2 × 15 mg/kg
– With implants in place PLUS rifampin‡ 2 × 450 mg p.o. PLUS rifampin‡ 2 × 600 mg p.o.
p.o. = oral treatment * Not available in all countries for this indication. In Germany, the 5-g fosfomycin dosage form for intravenous use is available; in most other countries, 2-, 4-
and 8-g dosage forms for intravenous fosfomycin are available. A daily dosage of 12–24 g intravenous fosfomycin is licensed, which can be administered as 3–4 × 5 g, 2–3 × 8
g or 3–6 × 4 g. † A single loading dose can be used in critically ill patients (1 × 25–30 mg/kg). Vancomycin trough serum concentration: 15–20 mg/l, measure after any dosage
change before the fourth dose and at any relevant change of serum creatinine. ‡ Start rifampin as soon as drainages are removed and wounds are dry; in combination with
vancomycin start rifampin only if vancomycin trough serum levels are in the therapeutic range (15–20 mg/l), and consider an earlier switch to an oral treatment combination with
better cerebrospinal fluid penetration than vancomycin. § Monitor serum creatinine and aminoglycoside trough levels every other day. For enterococci do not use aminoglycosides
if high-level resistant. ¶ If the higher dosage form of 2.2 g is not available, 3 × 1.2 g can be used instead.
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rifampin monotherapy in CSF, leading to treatment fail-
ure [10]. For ciprofloxacin, CSF levels reach about 26% of
plasma levels [22, 28–30].
Intravenous fosfomycin can be considered for the treat-
ment of CNS infections because of its activity against
most relevant pathogens, synergy with other antibiotics
and sufficient penetration across the blood-brain barrier in
both noninflamed (27%) and inflamed meninges (50–70%)
[31]. In a prospective, multicentre study (NCT01173575)
including patients with severe bacterial infections from 12
intensive care units in Germany and Austria, a subgroup
of patients treated with fosfomycin was analysed [32].
Most patients had severe CNS infections (22%), followed
by pneumonia (15%), bone and joint infections (11%),
abdominal infections (11%) and bacteraemia (11%). The
overall clinical success was favourable in 81.3% (148/182)
of cases, and in 84.8% (39/46) of patients with ≥1 mul-
tidrug resistant pathogen. These data suggest that intra-
venous fosfomycin is an effective and safe combination
partner for the treatment of severe bacterial infections.
Intraventricular antimicrobial treatment is not routinely
recommended [16]. However, it can be considered in pa-
tients with a poor response to systemic therapy or in the
case of multidrug resistant difficult-to-eradicate pathogens.
The main advantage is that the blood-brain barrier is by-
passed and high intraventricular concentrations can be
reached, but evidence for this treatment modality, especial-
ly dosing recommendations are sparse.
In selected patients, implant retention is possible. Prereq-
uisites for implant retention are acute infections with im-
mature biofilms (≤6 weeks), availability of biofilm-active
treatments and adequate soft tissue coverage of the implant
[17]. Prolonged biofilm-active treatment for 12 weeks
eradicates the biofilm thereafter. In chronic infections (>6
weeks) implant removal or exchange in a one- or two-
stage procedure with only a short implant-free interval of
14 days is recommended to remove the mature biofilm.
This surgical strategy is followed by usually 12 weeks of
biofilm-active treatment. If intraoperative culture results
are negative in the case of a two-stage implant exchange,
a shorter treatment duration of 4–6 weeks is possible. De-
spite negative intraoperative culture results during reim-
plantation, which usually is performed under antimicrobial
treatment, treatment continuation is suggested, as culture
results under antimicrobial treatment might be false nega-
tive. And an infection relapse can be associated with dev-
astating complications for the patient, if, for example, an-
other surgery is needed.
A difficult-to-treat implant-associated infection is present
if the causative pathogen is not susceptible to biofilm-
active therapy (e.g., rifampin-resistant staphylococci,
quinolone-resistant gram-negative bacilli and Candida
spp.). Eradication of infection is only possible with implant
Table 4: Targeted oral treatment for intra- or extradural infections (patient’s renal function and body weight must be taken into account). Rifampin treatment is only indicated if an
implant is involved.
Pathogen Extradural infection Intradural infection
Staphylococcus spp. Cotrimoxazole 3 × 960 mg OR
clindamycin 3 × 600 mg OR
doxycycline* 2 × 100 mg
Cotrimoxazole 3 × 1920 mg OR
doxycycline* 2 × 100 mg
– With implants in place Levofloxacin 2 × 500 mg OR
cotrimoxazole 3 × 960 mg OR
doxycycline* 2 × 100 mg OR
fusidic acid 3 × 500 mg
all PLUS
rifampin† 2 × 450 mg
Cotrimoxazole 3 × 1920 mg OR
moxifloxacin 1 × 4 00 mg OR
doxycycline* 2 × 100 mg
all PLUS
rifampin† 2 × 600 mg
Streptococcus spp. Amoxicillin 3 × 1 g OR
doxycycline* 2 × 100 mg OR
clindamycin 3 × 600 mg
Prolonged i.v. treatment (e.g., outpatient treatment with ceftriaxone
1 × 2 g i.v.), then:
moxifloxacin 1 × 400 mg
Enterococcus spp. Penicillin-susceptible Amoxicillin 3 × 1 g OR
doxycycline 2 × 100 mg
Prolonged i.v. treatment, then:
linezolid 2 × 600 mg OR
doxycycline 2 × 100 mg
Penicillin-resistant Linezolid 2 × 600 mg OR
doxycycline 2 × 100 mg
Prolonged i.v. treatment, then:
Linezolid 2 × 600 mg OR
doxycycline 2 × 100 mg
Cutibacterium spp. Amoxicillin 3 × 1 g OR
levofloxacin 2 × 500 mg OR
doxycycline* 2 × 100 mg OR
clindamycin 3 × 600 mg
Moxifloxacin 1 × 400 mg OR
doxycycline* 2 × 100 mg
– With implants in place all PLUS rifampin† 2 × 450 mg all PLUS rifampin† 2 × 600 mg
Enterobacteriaceae Ciprofloxacin 2 × 750 mg OR
cotrimoxazole 3 × 960 mg
Prolonged i.v. treatment, then:
cotrimoxazole 3 × 1920 mg OR
ciprofloxacin 2 × 750 mg
– With implants in place Ciprofloxacin 2 × 750 mg Ciprofloxacin 2 × 750 mg
Non-fermenters (e.g. P. aeruginosa, Acinetobacter spp.) Ciprofloxacin 2 × 750 mg Prolonged i.v. treatment, then:
ciprofloxacin 2 × 750 mg
– With implants in place Ciprofloxacin 2 × 750mg Ciprofloxacin 2 × 750 mg
Culture-negative infection Levofloxacin 2 x 500 mg PLUS
clindamycin 3 x 600 mg
OR
levofloxacin 2 x 500 mg PLUS
cotrimoxazole 3 x 960 mg
Prolonged i.v. treatment, then:
cotrimoxazole 3 x 1920 mg PLUS
moxifloxacin 1 x 400 mg
– With implants in place Levofloxacin 2 × 500 mg PLUS
rifampin† 2 × 450 mg
Moxifloxacin 1 × 400mg PLUS
rifampin† 2 × 600 mg
i.v. = intravenous * Minocycline (2 × 100 mg) is equivalent to doxycycline. † Start rifampin as soon as all drainages are removed, and wounds are dry.
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removal and antimicrobial treatment without any implant
in place for 1–6 weeks, depending on the pathogen and
the infection site as described below. Preferably, antibiotic
treatment should be continued until reimplantation to avoid
any viable microorganism to regrow.
If implant removal is not feasible, long-term antimicrobial
suppression therapy can be an alternative, but this, how-
ever, causes patient discomfort and might be associated
with adverse effects. According to the susceptibility pat-
tern, cotrimoxazole and doxycycline are alternatives for in-
tradural suppression treatment, with the addition of clin-
damycin if blood-brain barrier penetration is not necessary
in the case of extradural infections. Streptococcal implant-
associated infections on orthopaedic implants have been
shown to be difficult to eradicate, therefore a suppression
treatment for at least 1 year, possibly also longer if well
tolerated, is necessary [33].
Specific infections
Craniotomy- and cranioplasty-associated infections
To reach intracranial structures for brain biopsies, abscess
or haemorrhage drainage, clipping of vascular malforma-
tions or skull base tumour surgery, a bone flap is removed
and re-fixated with titanium plates or clamps. This proce-
dure is called craniotomy. If a larger bone flap is removed
and not immediately replaced in decompression surgery af-
ter trauma, malignant cerebral infarction or intracerebral
bleeding or in case of an infected bone flap, the procedure
is called craniectomy. The removed bone flap can be cry-
opreserved and reinserted at a later stage, which is called
autologous cranioplasty. In cases of skull trauma, chron-
ic bone flap infection or bone flap resorption, where the
bone flap is not reusable owing to multiple fragments, ma-
ture biofilm or aseptic bone necrosis, a synthetic cranio-
plasty is used (polyether ether ketone [PEEK], poly methyl
methacrylate [PMMA] or titanium) [34, 35]. Risk factors
for infection are diabetes, presence of an EVD, CSF leak-
age, intracerebral haematoma and tumour surgery [36–41].
Craniotomy- and cranioplasty-associated infections usual-
ly manifest early after surgery (within the first month) and
most commonly are caused by pathogens of the skin flora,
namely staphylococci [36–39, 42–44]. Clinical presenta-
tion includes wound healing problems and purulent wound
drainage, but also fever, headache, seizures or focal neuro-
logical deficits [42, 43, 45]. The infection rate is lower for
craniotomies (0.3–12%) than for cranioplasties (1–24.4%)
[2]. For cranioplasties, the infection rate is independent
from the material (autologous vs synthetic) [35, 46–48]. In
a recent cohort study there was an association of very ear-
ly cranioplasty (within 14 days of craniectomy) with infec-
tion, but there is no other evidence that delayed cranioplas-
ty is associated with a lower infection risk [35, 46, 49, 50].
Nevertheless, most cranioplasties are performed with a de-
lay of 7.3 months on average (range 1–40 months), leaving
the patient with a disfiguring skull deformity without brain
protection, with disturbed CSF circulation and the possibil-
ity of a sinking flap syndrome with progressive neurologi-
cal deterioration [3, 46]. For this reason, an earlier cranio-
plasty should be considered.
As superficial and deep compartments are not anatomically
separated early after surgery and because of the thin layer
of soft tissue covering craniotomies and cranioplasties, all
infections should be considered deep wound infections and
therefore craniotomy- or cranioplasty-associated. Current
clinical practice usually includes removal of the infected
implant or bone flap and delayed cranioplasty once infec-
tion is eradicated. A new concept, extrapolated from im-
plant-associated infections in orthopaedic surgery, allows
surgical debridement and implant retention in acute infec-
tions in selected patients where biofilm-active therapy is
available and soft tissue coverage is sufficient, or a one-
or two-stage implant exchange with only a short implant-
free interval of 2 weeks (fig. 2) [17]. Afterwards, the pa-
tient is treated for 12 weeks with a biofilm-active thera-
py (tables 2, 3 and 4) [17]. With this concept the patient
stays for only a short time, if at all, with a disfiguring skull
deformity without brain protection, improving quality of
life. This concept has recently been shown to be effective
in neurosurgical patient populations [43, 44, 51]. Of 12
patients with an autologous craniotomy-associated infec-
tion and resection craniectomy, in 10 (83%) immediate ti-
tanium cranioplasty with the administration of intravenous
(range 3–8 weeks) and oral (range 0–16 weeks) antibiot-
ic treatment was successful [44]. In another study, debride-
ment and bone flap retention were shown to be effective in
10 of 11 patients (91%) together with intravenous (range
2–6 weeks) and oral (range 0–6 weeks) antibiotic treatment
[51]. These small studies confirm that implant retention
or immediate exchange are alternatives to removal. Al-
though a suboptimal antibiotic treatment was used in most
patients (no biofilm-active treatment), successful outcome
was observed. Owing to the small patient numbers, one
can only conclude that surgical debridement is obviously a
main pier in the treatment concept “debridement and im-
plant retention” and contributes to the high treatment suc-
cess in combination with the biofilm-active treatment. In
a larger cohort, an infection-free survival of 87% during a
12-month follow-up was achieved by applying the concept
suggested here, including optimised biofilm-active therapy
[43]. In univariate analysis, inadequate antimicrobial ther-
apy (no biofilm-active treatment for the defined treatment
period) was associated with treatment failure.
Neurostimulator-associated infections (deep brain and
spinal cord stimulators)
Deep brain stimulators are being increasingly used in
movement disorders, such as Parkinson’s disease or dysto-
nia, whereas spinal cord stimulators are particularly used
to treat chronic back pain. A stimulator system includes
leads and electrodes, which are placed in the brain (deep
brain stimulators) and the spinal epidural space (spinal
cord stimulators). Wires connect the leads and electrodes
with the generator, which is placed in the subcutaneous tis-
sue of the chest for deep brain stimulators or the abdomen
for spinal cord stimulators (fig. 3). Infections occur at the
generator pocket in 31–85% (so-called pocket infection),
but may also affect wires (15–69%), whereas leads and
electrodes with brain or epidural abscesses are rarely in-
volved; the predominant pathogens are staphylococci and
other members of the skin flora [52–55]. The infection rate
for deep brain stimulators lays between 4.5% and 6.5%,
with the majority presenting within 3 months of implanta-
tion [52, 54–58]. For spinal cord stimulators an infection
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rate of 5% is found, with 38% manifesting as early im-
plant-associated infections [53, 59–61].
In cases of infection, device removal or a lead/electrode-
sparing procedure with partial explantation of the device
and reimplantation weeks after the infection is cured is rec-
ommended by several authors. However, this procedure is
associated with significant morbidity and inconvenience
for the patient, as multiple (brain) surgeries are necessary,
and symptoms recur during the implant-free interval. In ad-
dition, high healthcare costs due to the lost stimulator sys-
tem can be expected [52, 54]. Therefore, our suggestion
includes again extrapolating the treatment algorithm from
orthopaedic surgery, which allows the implant to be re-
tained or only partially exchanged in selected patients. Pre-
requisites for this strategy are acute infections, availability
of biofilm-active therapy and adequate soft tissue coverage
of the implant. Thereafter, a 12-week biofilm-active thera-
py is followed (tables 2, 3 and 4) [17]. Depending on the
infected part of the neurostimulator, we suggest the follow-
ing procedures (fig. 4). In acute pocket infections, genera-
tors can be debrided and retained if biofilm-active therapy
is available. Preferably, the implantation site of the genera-
tor should be changed because of the usually poor soft tis-
sue condition in infection. Leads, electrodes and wires can
be retained. If there is an extracranial or spinal wire infec-
tion, wires should be changed as far as possible, but gen-
erator, leads and electrodes can be retained. The antimicro-
bial treatment and its duration depend on the infected part
of the stimulator and the surgical strategy chosen. In the
case of a difficult-to-treat infection, where no biofilm-ac-
tive therapy is available, long-term antimicrobial suppres-
sion therapy is an alternative, especially if device removal
is deemed impossible. Device removal is mandatory in
the event of life-threatening infections including lead- and
electrode-associated brain or epidural abscesses, or menin-
gitis.
Ventriculo-peritoneal and ventriculo-atrial cere-
brospinal fluid shunt-associated infections
VP and VA shunt systems drain CSF in patients with
chronic hydrocephalus from the cerebral ventricles to the
peritoneal cavity or right cardiac atrium, respectively. In
both CSF shunt systems the infection rate is similar at
4–16%, but complications are more common and usually
more severe in VA shunts [2]. The latter require more sur-
gical revisions and cause high morbidity in cases of distal
shunt disconnection, intracardiac thrombus formation and
shunt migration, which may result in myocardial perfora-
tion [62]. There are many risk factors for CSF shunt-asso-
ciated infections, including previous CSF shunt infection,
postoperative CSF leakage, revision surgery, concomitant
EVD and the use of a neuroendoscope [63, 64]. CSF shunt
Figure 2: Management algorithm for craniotomy- and cranioplasty-associated infections. Antibiotics with biofilm activity: rifampin for
staphylococci and Cutibacterium spp.; fluoroquinolones for gram-negative bacilli.MRI = magnet resonance imaging; CT = computed tomogra-
phyBlue frame = intradural treatment; green frame = extradural treatment
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systems coated with antibiotics (e.g., clindamycin and ri-
fampin) have been recently shown to decrease infection
rate [65]. However, the risk of emergence of antimicrobial
resistance by using local antibiotics is of concern, partic-
ularly for rifampin, as resistance may develop rapidly as
a consequence of point mutation. This risk has been ob-
served in rifampin-soaked vascular grafts in vitro [66]. Ri-
fampin is the only biofilm-active antibiotic against staphy-
lococci and development of resistance means that
eradication of biofilm infection is impossible. Combina-
tion of rifampin with clindamycin usually does not prevent
development of resistance as many staphylococci are resis-
tant to clindamycin.
Patients with CSF shunt-associated infections usually pre-
sent early within the first month of CSF shunt placement
and the dominant pathogens are staphylococci and
Cutibacterium spp. [10, 67]. Patients often present with
few or no clinical signs and symptoms [10, 67]. Clinical
presentation differs between VP and VA shunt-associated
infections, especially if the distal shunt part is infected [10,
67]. If the distal VP shunt part is infected, patients may
present with abdominal pain or discomfort due to peritoni-
tis, intraabdominal pseudocysts or intestinal shunt perfo-
ration; if the distal VA shunt part is infected, stigmata of
right-sided endocarditis can be present including contin-
uous bacteraemia and septic lung emboli. In long-lasting
VA shunt-associated low-grade infection, shunt nephritis,
an immune complex-mediated glomerulonephritis, is a rare
complication [10, 68–70]. In case of a low-grade infection
of the proximal shunt part, shunt dysfunction with progres-
sive signs of hydrocephalus, namely headache, vomiting
and seizures, may be the only hint for infection. In high-
grade infections, on the other hand, patients can present
with acute meningitis or brain abscess, which represent
emergency indications for CSF shunt removal. Fever, al-
though the most common clinical finding, is present in on-
ly 78% [10, 67]. As clinical signs and symptoms often are
non-specific, CSF analysis is of utmost importance. Ac-
cording to current literature, CSF from shunt valve punc-
ture has a higher diagnostic yield than CSF from lumbar
puncture or ventricular CSF: the microbiological yield was
68–91% in shunt valve puncture, compared with 8–45% in
lumbar and 20–70% in ventricular CSF [10, 67]. The same
is true for the CSF cell count, which is elevated in only
80% overall, but is definitively higher in CSF from shunt
valve and lumbar puncture, with a median of 484 cells/
µl and 573 cells/µl, respectively, compared with ventricu-
lar CSF with a median of 8 cells/µl [10]. These findings
Figure 3: Illustration of a deep brain stimulator.
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again can be explained by the biofilm concept: microor-
ganisms and leucocytes are close around biofilms on the
shunt valve, which is supported by the high positivity rate
of shunt tip cultures of 49–78% (which for sure is underes-
timated, as in both studies sonication of the implants was
not available). Other explanations for these CSF findings
could be differences in CSF circulation in patients with hy-
drocephalus, but also the retrospective study design where
a sampling and treatment bias cannot be excluded [10, 67].
In VA shunt-associated infections, blood cultures are an
important diagnostic tool with positivity rates >80% due to
the intravascular location of the distal shunt part [10].
Published studies on treatment modalities are very con-
tradictory. An older randomised study by James et al. of
50 patients with CSF shunt-associated infections compared
shunt removal, one-stage shunt exchange and shunt reten-
tion. Antibiotic treatment consisted of 2 weeks intraven-
tricular and 3 weeks intravenous application of antibiotics
without activity against biofilms [71]. High cure rates with
shunt removal (95%) and one-stage shunt exchange (88%)
contrasted with a high failure rate (64%) for shunt reten-
tion, underlining the need for surgery to cure implant-as-
sociated infections. In a retrospective study of 78 adult pa-
tients with CSF shunt-associated infections, 81% received
Figure 4: Management algorithm for neurostimulator-associated infections. Antibiotics with biofilm activity: rifampin for staphylococci and
Cutibacterium spp.; fluoroquinolones for gram-negative bacilli.CNS = central nervous system; IV = intravenousBlue frame = intradural treat-
ment; green frame = extradural treatment1 Rifampin-resistant staphylococci, quinolone-resistant gram-negative bacilli and Candida spp.2 An-
tibiotics for long-term antimicrobial suppression treatment are cotrimoxazole and doxycycline for intradural infections and cotrimoxazole, doxy-
cycline and clindamycin for extradural infections
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a combined surgical and antimicrobial treatment – includ-
ing shunt removal (47%) and a one- (10%) or two-stage
(23%) shunt exchange with or without an intercurrent EVD
[10]. The overall cure rate in those patients was high at
98%. Interestingly, the 19% of patients without surgery
showed a cure rate of 87%, which contrasts with James’
study and might be explained by the optimised antimi-
crobial therapy with biofilm activity in the more recent
study [10]. In another retrospective analysis the surgical
treatment concept included CSF shunt removal (28%) and
one- (22%) or two-stage (43%) shunt exchange, where-
as the strategy of antibiotics alone has progressively been
abandoned over time (only 7%) [67]. The cure rate over-
all was lower at 70% (17% with antibiotics alone, 31%
with one-stage and 89% with two-stage exchange, 83%
with shunt removal), and might be explained by the fact
that many patients with staphylococcal infections did not
receive biofilm-active treatment with rifampin, and also by
the strategy of distal shunt externalisation with secondary
infection of the externalised shunt in five patients. Nev-
ertheless, the only risk factor for treatment failure in this
study was CSF shunt retention (odds ratio 46.04, 95% con-
fidence interval 5.30–399.88) [67].
Based on these studies, showing that either CSF shunt re-
tention in acute infections or one-stage shunt exchange in
chronic infections where biofilm-active therapy is avail-
able are valuable treatment alternatives with lower morbid-
ity for the patient, the following treatment algorithm is sug-
gested (fig. 5). If the CSF shunt is retained or exchanged
in a one-stage procedure, 12 weeks of biofilm-active ther-
apy is administered. It must be emphasised that CSF shunt
retention is not possible in cases of acute ventriculitis or
meningitis, brain abscess, shunt dysfunction, skin erosion
over the shunt system or gut perforation. If the CSF shunt
is removed or exchanged in a two-stage procedure, the du-
ration of treatment and implant-free interval is guided by
the intraoperative culture results and the pathogen. If the
CSF shunt is removed, one can expect CSF infection to be
eradicated after 5–7 days for coagulase-negative staphylo-
cocci and Cutibacterium spp., after 14 days for Staphylo-
coccus aureus, Streptococcus spp., Enterococcus spp. and
culture-negative infections, and after 21 days in the case of
gram-negative bacilli [16]. If intraoperative cultures dur-
ing CSF shunt replacement are still positive, a 12-week
biofilm-active treatment is followed; in the case of nega-
tive intraoperative culture results, 4–6 weeks of treatment
is recommended to eradicate any remaining microorgan-
isms (tables 2, 3 and 4). In cases where a difficult-to-
treat pathogen is isolated with a new CSF shunt in place,
a long-term antimicrobial suppression therapy is indicated
(cotrimoxazole or doxycycline), if shunt removal is not
an option. As treatment failures occurred in patients with
CSF shunt-associated infections due to coagulase-negative
staphylococci treated with intravenous vancomycin and
oral rifampin according to the susceptibility testing, one
can speculate that insufficient vancomycin CSF penetra-
tion leads to rifampin monotherapy with development of
resistance, although additional subtherapeutic vancomycin
blood levels cannot be excluded owing to the retrospective
design of the study [10]. Therefore, optimised treatment
combinations with CSF penetration in intradural infections
are warranted. For VA shunt-associated endocarditis pro-
longed intravenous treatment might be adequate [72].
Infections associated with external ventricular and
lumbar cerebrospinal fluid drainages
EVD and ELD are temporary implants mostly used to treat
acute hydrocephalus after intracranial bleeding or severe
craniocerebral injury. Because of the temporary placement,
management of EVD- and ELD-associated infections dif-
fers from that of CSF shunt-associated infections, as no
biofilm-active treatment is necessary. However, EVD- and
ELD-associated infections can be challenging to manage,
especially if the patient is dependent on an external CSF
drainage and needs a permanent CSF shunt, which often
must be placed timely and at the time when the infected
EVD or ELD is removed. Up to 44% of patients with an
EVD or ELD need a CSF shunt [73]. EVD- and ELD-as-
sociated infections occur in 2–22%, with an average in-
fection rate of 8% [2]. The most common pathogens are
staphylococci and other members of the skin flora such as
Cutibacterium spp., but polymicrobial infections also oc-
cur [73, 74]. Risk factors for infection are cranial frac-
ture with CSF leakage, duration of CSF catheterisation (≥8
days), repetitive CSF sampling from EVD or EVD irriga-
tion [75–78]. Whether the EVD was placed in the operat-
ing room or at the bedside in an intensive care unit or emer-
gency department, and whether a silver-coated EVD or
ELD was used did not have an impact on the infection rate;
a tunnelled EVD, however, was associated with a lower
rate of infection [38, 74, 78–80]. We absolutely discourage
the use of rifampin-coated EVDs and ELDs, which expose
pathogens in the CSF to rifampin monotherapy and select
for rifampin-resistant bacteria (mainly coagulase-negative
staphylococci) [81]. This will prevent cure of an ensuing
CSF shunt-associated infection, as no biofilm-active thera-
py is available.
The diagnosis of EVD- or ELD-associated infections is
challenging. Clinical signs and symptoms, as well as re-
sults of CSF analyses, overlap with those of the underlying
disease including CSF haemorrhage causing a sterile in-
flammation [5]. In addition, signs of CNS infection can be
masked by the low level of consciousness due to the under-
lying condition, as well as by the treatment with sedative
drugs. Therefore, a high level of clinical suspicion is need-
ed. Remarkably, 23% of patients presented with meningi-
tis only within 10 days after EVD had been removed [25,
73]. In a retrospective study with 39 patients, clinical and
CSF analyses were compared at three different time-points,
the time of EVD insertion, 48 hours before occurrence of
EVD-associated infection and at the time of CSF culture-
positive infection [82]. The only significant indicators for
infection were a higher incidence of fever, an increased
respiratory rate and a decreased mental state; CSF para-
meters did not differ. In another study with 48 patients,
clinical and CSF parameters were compared between the
time-points of EVD insertion and EVD-associated infec-
tion: fever was more common in EVD-associated infection
(79 vs 15%), as were headache, vomiting and neck stiff-
ness (31 vs 6%), and an increased CSF cell count (175 vs
46 cells/µl) [73]. As there is a lack of more sensitive and
specific criteria, EVD-associated infection is mostly diag-
nosed on the basis of CSF pleocytosis and the presence of
fever, resulting in a significantly higher rate of postulat-
ed than microbiologically proven infections, which is con-
sidered the gold standard [83]. Some studies found an in-
creased cell index and CSF lactate (at a cut-off of 4 mmol/
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l) to be predictive for EVD-associated infections [84–87].
The cell index is calculated as the ratios of white blood cell
count and red blood cell count in the CSF and the blood.
Lunardi’s study showed, that a cut-off point of 2.9 was in-
dicative for infection, as was a 4.33-fold increase of the
cell index over time [86].
Based on the above-mentioned findings, we suggest the
following management. The exclusion of an alternative
nosocomial infection focus is mandatory in every febrile
patient with an EVD or ELD. If the suspicion for an EVD-
or ELD-associated infection is high and the CSF analysis
compatible with infection (CSF leucocyte count >300
cells/µl or increasing cell index, lactate >2.1 mmol/l, de-
creased glucose CSF/blood ratio <0.5), CSF should be
sampled for microbiological culture and empirical antimi-
crobial treatment started, for example with intravenous
vancomycin plus either ceftriaxone, cefepime or cef-
tazidime according to local surveillance data (table 2). In-
traventricular antimicrobial therapy is of no proven benefit
if the patient responds to intravenous treatment [16]. As
EVD and ELD are intercurrent implants only, use of ri-
fampin as biofilm-active therapy is strongly discouraged.
Rifampin might be needed later if a permanent CSF shunt
is inserted and becomes infected. According to the
causative pathogen, treatment duration is 7 days in the
case of low-virulent pathogens such as coagulase-negative
staphylococci and Cutibacterium spp., 14 days in the case
of S. aureus, Streptococcus spp., Enterococcus spp. and
culture-negative infections, and 21 days if gram-negative
bacilli are isolated (table 3) [16]. EVD and ELD manipula-
tions should be restricted as much as possible, as they are
associated with an increased risk of infection; according-
ly, daily CSF sampling and prophylactic EVD or ELD ex-
change are not recommended [16, 88, 89]. But in the event
of a high-grade infection (S. aureus, gram-negative bacilli
or Candida spp.), or of an inadequate response to therapy,
the EVD or ELD should be changed, if still needed.
Conclusions
With the technical developments in neurosurgery, increas-
ing numbers of neurosurgical implants are used and there-
fore device-associated infections in neurosurgery are be-
coming more and more relevant. There are few validated
diagnostic and treatment approaches, and most recommen-
dations are extrapolated from other implant-associated in-
Figure 5: Management algorithm for CSF shunt-associated infections.CSF = cerebrospinal fluid; EVD/ELD = external ventricular/lumbar
drainage; IV = intravenousBlue frame = intradural treatment1 CSF leucocyte count > 5x106 cells/µl, with predominance of granulocytes, CSF
lactate > 1.9 mmol/l, CSF total protein > 0.45 g/l, glucose CSF/blood ratio < 0.52 For low-virulent microorganisms, including coagulase-nega-
tive staphylococci and Cutibacterium spp., reimplantation after 5–7 days; for S. aureus, Streptococcus spp., Enterococcus spp. and culture-
negative infections 14 days; for Enterobacteriaceae and P. aeruginosa 21 days [16]3 Rifampin-resistant staphylococci, quinolone-resistant
gram-negative bacilli and Candida spp.4 Antibiotics for long-term antimicrobial suppression treatment are cotrimoxazole and doxycycline
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fections, although the evidence for the success of this ex-
trapolation to neurosurgical patients is sparse and has not
been evaluated in large patient populations. As biofilms
are involved, management is challenging and should fol-
low well-known and clinically validated interdisciplinary
concepts from orthopaedic or trauma surgery, where high
cure rates of >90% are achieved. Interdisciplinarity is cru-
cial for successful outcome. Sonication of the removed im-
plants and prolonged culture incubation significantly im-
prove microbiological diagnosis. Treatment includes
surgery, with a thorough debridement and stage-specific
implant management, i.e., debridement and retention in
acute infections, or a one- or two-stage implant exchange
in chronic infections. In addition, 4–12 weeks of a biofilm-
active treatment is usually needed. Cure without implant
removal or with a one-stage exchange are therefore new
treatment options, which decrease morbidity, especially as
removal of neurosurgical implants is often difficult or im-
possible owing to the risk of damaging brain tissue or caus-
ing intracerebral bleeding. With this strategy, the number
of operations can be reduced and the quality of patients’
lives improved. With less invasive surgical approaches, an-
timicrobial treatment needs to be optimised using biofilm-
active therapies. If the intradural compartment is infected,
special attention to antibiotic penetration across the blood-
brain barrier is needed.
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